Shortened Cardio-Metabolic Mouse Model of HFpEF

Current preclinical murine models of heart failure with preserved ejection fraction (HFpEF) require prolonged modeling periods, posing significant challenges for rapid screening in drug development. To address this challenge, WuXi Biology presented a poster at AHA 2025 describing the establishment of a novel, shortened, multifactorial HFpEF mouse model that couples obesity, hyperglycemia, hypertension, and cardiac hypertrophy to mirror the cardiometabolic phenotypes observed in human patients.

To validate this model, the authors present a case study using LCZ696 (sacubitril/valsartan).  Administration of LCZ696 resulted in significant attenuation of cardiometabolic abnormalities, with restored diastolic function and reduced cardiac hypertrophy and myocardial fibrosis, highlighting how this model closely mimics human HFpEF.

Poster_AHA_2025_Cardio-Metabolic Mouse Model of HFpEF

Download